Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma | Zendy

Miodrag Dragoj | Zendy; Zorica Milošević | Zendy; Jasna Banković | Zendy; Nikola Tanić | Zendy; Milica Pešić | Zendy; Tijana Stanković | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma

Author(s) -

Miodrag Dragoj,

Zorica Milošević,

Jasna Banković,

Nikola Tanić,

Milica Pešić,

Tijana Stanković

Publication year - 2016

Publication title -

cellular oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.698

H-Index - 40

eISSN - 2211-3436

pISSN - 2211-3428

DOI - 10.1007/s13402-016-0304-6

Subject(s) - cancer research , cxcr4 , doxorubicin , focal adhesion , viability assay , flow cytometry , metastasis , lung cancer , abcc1 , chemokine receptor , biology , medicine , cell culture , cancer , chemokine , pathology , signal transduction , receptor , immunology , microbiology and biotechnology , chemotherapy , gene , biochemistry , genetics , atp binding cassette transporter , transporter

Current high lung cancer mortality rates are mainly due to the occurrence of metastases and therapeutic resistance. Therefore, simultaneous targeting of these processes may be a valid approach for the treatment of this type of cancer. Here, we assessed relationships between CXC chemokine receptor type 4 (CXCR4) and focal adhesion kinase (FAK) gene expression levels and expression levels of the drug resistance-related genes ABCB1 and ABCC1, and tested the potential of CXCR4 and FAK inhibitors to reverse doxorubicin (DOX) resistance and to decrease the invasive capacity of non-small cell lung carcinoma (NSCLC) cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research